Future Perspectives on the Treatment of NSCLC
Dr Edgardo Santos highlights key takeaways from the presented data and provides insights into how these findings could shape the future landscape of healthcare directions.
EP: 1.Beamion Lung 1: Zongertinib (BI 1810631) in Advanced HER2+ NSCLC
EP: 2.Expert Analysis on Recent Developments in DESTINY-Lung01 and DESTINY-Lung02 Trials
EP: 3.Expert Perspectives on the Latest TROPION-Lung01 Data
EP: 4.EMPOWER-Lung3: Cemiplimab Plus Chemotherapy in Advanced NSCLC
EP: 5.EMPOWER-Lung1 and 3 Squamous Subgroup Analysis: Expert Insights
EP: 6.Future Perspectives on the Treatment of NSCLC
This is a video synopsis/ summary of an OncLive Insights® featuring Edgardo S. Santos, MD, FACP, FCCP.
In conclusion, Santos summarized key lung cancer advances from the 2023 World Conference on Lung Cancer and the European Society of Medical Oncology Congress. He covered data on new targeted therapies such as the HER2 antibody-drug conjugate trastuzumab deruxtecan and datopotamab deruxtecan for molecularly selected patients with non–small cell lung cancer. Beyond targets, combination approaches are ongoing, including antibody-drug conjugates with immunotherapy. However, developing effective regimens for immunotherapy-refractory lung cancer remains an unmet need. Santos expressed optimism that new treatment options are on the horizon for patients with lung cancer, both with and without targetable genomic alterations.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
